KANGO SUJAY 4
4 · ACCELERON PHARMA INC · Filed Mar 4, 2021
Insider Transaction Report
Form 4
KANGO SUJAY
SVP, Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2021-03-02$40.61/sh+5,000$203,050→ 24,396 total - Sale
Common Stock
2021-03-02$135.48/sh−2,699$365,661→ 21,697 total - Sale
Common Stock
2021-03-02$136.24/sh−1,501$204,496→ 20,196 total - Sale
Common Stock
2021-03-02$137.12/sh−600$82,272→ 19,596 total - Sale
Common Stock
2021-03-02$138.15/sh−200$27,630→ 19,396 total - Exercise/Conversion
Option to Purchase Common Stock
2021-03-02−5,000→ 35,000 totalExercise: $40.61Exp: 2028-03-01→ Common Stock (5,000 underlying)
Footnotes (5)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.80 to $135.78 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $135.90 to $136.46 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.02 to $137.60 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4.
- [F5]The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.